Table 3.
Characteristics of the publications (59 patients, 92 radiotherapy treatments).
| CDK4/6 inhibitors | Number of patients included | Palbociclib [38], [39], [40], [41], [42] | Ribociclib [41], [43] | Abemaciclib [42] |
|---|---|---|---|---|
| Number of patients | 59 (100%) | 46 (79%) | 8 (13.5%) | 5 (8.47%) |
| Irradiation intent | Palliative (n = 32) Curative (n = 27) |
Palliative (n ≥ 16)* Curative (n ≥ 19)* |
Palliative (n ≥ 5)* Curative (n ≥ 0)* |
Curative (n = 5) |
| Irradiated sites (n = 92) | spine, pelvis bone extremity, brain, mediastinum, supraclavicular lymphadenopathy, calvarium bone | bone | brain | |
| Combined hormone therapy | Fulvestrant (n = 13) Letrozole (n = 10) |
Letrozole | Not reported | |
| Type of radiotherapy treatment | 3DCRT/IMRT/VMAT/SBRT | VMAT /3DCRT | SBRT | |
| Sequence of administration : CDK4/6-RT |
Pre : 13 Concurrent : 51 Post : 22 |
≥ 4 pre** ≥25 concurrent** ≥7 post** |
Concurrent | Not reported |
| Hematological toxicities grade ≥ 3 (11 = 18.6%) | 5 Myelotoxicity reported after systemic treatment | 1 Myelotoxicity reported after systemic treatment 1 grade greater than 3 | No increase of hematotoxicity | |
| Toxicity in the irradiation field grade ≥ 3 (6.7%) | −1 colitis −1 œsophagitis + skin |
2 radionecrosis but no information about CDK4/6(palbociclib or abemaciclib) |
* Patients from Ippolito trial are included here but their precise number is not reported.
** Patients from the Figura trial are included but their precise number is not reported.